-transparent.png){kind=logo}
In patients with pulmonary hypertension associated with congenital heart defects, ultrastructural abnormalities are observed in endothelial cells, which suggest heightened metabolic function. If endothelial production of the von Willebrand factor (vWF) is increased, this may be associated with abnormal interactions with platelets leading to worsening of the pulmonary hypertension. We therefore evaluated vWF in 30 patients with pulmonary hypertension (25 with congenital heart defects) and in 30 individuals with normal pulmonary arterial pressure (12 with congenital heart defects). We measured the antigenic (vWF: Ag) and biologic (VWF: rist) activity of vWF in plasma and assessed endothelial vWF: Ag directly by an immunoperoxidase stain applied to lung biopsy tissue. Because of considerable variance and small size, the group of five patients with pulmonary hypertension and without congenital heart defects were excluded from statistical analyses. Patients with pulmonary hypertension and congenital heart defects had significant higher vWF: Ag levels than individuals with normal pulmonary arterial pressure without congenital heart defects (p less than .05), whereas values in those with normal pressure and congenital heart defects were intermediate. In lung biopsy tissue available from 29 patients in this study and from 11 others we previously reported, immunostain of pulmonary arterial endothelium for vWF was intense (suggesting increased production) in 29 of 32 with pulmonary hypertension and congenital heart defects and in only one of eight with normal pulmonary arterial pressure and congenital heart defects (p less than .01). Only three patients with congenital heart defects and pulmonary hypertension and increased vWF: Ag, however, had increased vWF: rist. Compatible with this discrepancy was a loss of vWF high-molecular weight forms as determined by both crossed immunoelectrophoresis and multimeric analysis. Our results suggest that increased vWF in most patients with congenital heart defects and pulmonary hypertension is associated with increased production of a biologically deficient molecule lacking high-molecular weight forms.
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
October 2017,
Heart, lung & circulation,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
July 1975,
Japanese circulation journal,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
April 1999,
Circulation,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
January 1978,
Pediatria polska,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
September 2006,
European journal of clinical investigation,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
September 2006,
Revue des maladies respiratoires,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
September 1973,
Der Internist,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
January 1989,
Zeitschrift fur Kardiologie,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
January 1967,
Bibliotheca paediatrica,
M Rabinovitch, and
M Andrew, and
H Thom, and
G A Trusler, and
W G Williams, and
R D Rowe, and
P M Olley
December 1966,
Thoraxchirurgie und vaskulare Chirurgie,
